[
  {
    "ts": null,
    "headline": "Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative?",
    "summary": "Vertex Pharmaceuticals recently announced important updates on its investigational kidney disease therapy povetacicept, including FDA regulatory progress and upcoming data presentations, as well as new clinical data for its cystic fibrosis therapy ALYFTREK presented at a major medical conference. The only dual BAFF+APRIL inhibitor currently in pivotal trials for multiple kidney diseases, povetacicept strengthens Vertex's position in B cell-mediated disease innovation and broadens its...",
    "url": "https://finnhub.io/api/news?id=fb2a3f574e4428a42ebbc64de3bc892d3825e8f137eec758dd0053d81e5925d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761243414,
      "headline": "Did FDA Progress on Povetacicept and New Data for ALYFTREK Just Shift Vertex’s (VRTX) Investment Narrative?",
      "id": 137198335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals recently announced important updates on its investigational kidney disease therapy povetacicept, including FDA regulatory progress and upcoming data presentations, as well as new clinical data for its cystic fibrosis therapy ALYFTREK presented at a major medical conference. The only dual BAFF+APRIL inhibitor currently in pivotal trials for multiple kidney diseases, povetacicept strengthens Vertex's position in B cell-mediated disease innovation and broadens its...",
      "url": "https://finnhub.io/api/news?id=fb2a3f574e4428a42ebbc64de3bc892d3825e8f137eec758dd0053d81e5925d8"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference",
    "summary": "BOSTON, October 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington.",
    "url": "https://finnhub.io/api/news?id=0a94916b9e2e0b0aeb8739620fe155fba6360fc1d9ad288b4f60aec8d7fbd7a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761224400,
      "headline": "Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference",
      "id": 137198336,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, October 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington.",
      "url": "https://finnhub.io/api/news?id=0a94916b9e2e0b0aeb8739620fe155fba6360fc1d9ad288b4f60aec8d7fbd7a3"
    }
  },
  {
    "ts": null,
    "headline": "Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21 with a price target of $563. The analyst based the optimistic rating on the company’s strong growth potential […]",
    "url": "https://finnhub.io/api/news?id=52a2b6eba806086bd12445cc7a242b75f6702d474790affbcf4496538e0ff59a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761186945,
      "headline": "Bank of America Securities Remains Bullish on Vertex Pharmaceuticals Incorporated (VRTX)",
      "id": 137198337,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best long term low volatility stocks to buy right now. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on October 21 with a price target of $563. The analyst based the optimistic rating on the company’s strong growth potential […]",
      "url": "https://finnhub.io/api/news?id=52a2b6eba806086bd12445cc7a242b75f6702d474790affbcf4496538e0ff59a"
    }
  }
]